ClinicalTrials.Veeva

Menu
U

Universidade Estadual de Campinas | Faculdade de Ciencias Medicas - Centro de Pesquisa Clinica

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

ION-682884
Eplontersen
Diacerein
Metformin
Dexamethasone
Daratumumab
Daxdilimab
TAR-210
Thalidomide
D-VRd

Parent organization

This site is a part of Universidade Estadual de Campinas

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 24 total trials

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Cusatuzumab
Drug: Azacitidine

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Active, not recruiting
Bladder Cancer
Biological: Cetrelimab
Drug: TAR-200

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.

Enrolling
Generalized Myasthenia Gravis
Drug: Placebo
Biological: Telitacicept

The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with hereditary transthyreti...

Active, not recruiting
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Drug: Eplontersen
Locations recently updated

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's ch...

Enrolling
Non-Muscle Invasive Bladder Neoplasms
Drug: Gemcitabine
Combination Product: TAR-210

To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC).

Active, not recruiting
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Drug: Eplontersen
Drug: Placebo

This is a non-controlled, single-arm, open-label clinical trial to describe the PK, PD, immunogenicity and safety of ASNase. All subjects enrolled wi...

Active, not recruiting
Acute B-Cell Lymphoblastic Leukaemia
Drug: Spectrila®

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Ionis Pharmaceuticals logo
U
F
A
Amgen logo
Gilead Sciences logo
M
Novo Nordisk logo
O

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems